Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy
Pablo García‐Pavía(Instituto de Salud Carlos III), Perry Elliott(St Bartholomew's Hospital), Frank M. Bengel(Medizinische Hochschule Hannover), Dulce Brito(University of Lisbon), Yoshiki Sekijima(Université Paris-Sud), Sharmila Dorbala(Brigham and Women's Hospital), Franz Duca(Medical University of Vienna), Thibaud Damy(Inserm), Laura Obici(Amyloidosis Foundation), José Nativi-Nicolau(Mayo Clinic in Florida), Claudio Rapezzi(Boston University)
Cited by 173
Related Papers
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2013|3.4k
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease
|European Heart Journal|2020|1.8k